Turnstone Biologics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Turnstone Biologics's earnings have been declining at an average annual rate of -45.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 100% per year.
Información clave
-45.4%
Tasa de crecimiento de los beneficios
81.6%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | -100.0% |
| Rentabilidad financiera | -125.1% |
| Margen neto | n/a |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastos
Cómo gana y gasta dinero Turnstone Biologics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -75 | 18 | 1 |
| 31 Mar 24 | 0 | -75 | 19 | 0 |
| 31 Dec 23 | 19 | -55 | 18 | 0 |
| 30 Sep 23 | 30 | -52 | 18 | 31 |
| 30 Jun 23 | 40 | -51 | 18 | 31 |
| 31 Mar 23 | 82 | -29 | 18 | 0 |
| 31 Dec 22 | 73 | -31 | 18 | 0 |
| 31 Dec 21 | 101 | 3 | 14 | 0 |
Ingresos de calidad: TSBX is currently unprofitable.
Margen de beneficios creciente: TSBX is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Insufficient data to determine if TSBX's year-on-year earnings growth rate was positive over the past 5 years.
Acelerando crecimiento: Unable to compare TSBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: TSBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rentabilidad financiera
Alta ROE: TSBX has a negative Return on Equity (-125.05%), as it is currently unprofitable.